期刊文献+

阿塞那平中杂质的合成

Synthesis of the impurities from asenapine
原文传递
导出
摘要 目的:为加强对阿塞那平药物的质量控制,合成了阿塞那平的4个杂质,其中杂质C和杂质D的合成为首次报道。方法:以11-氯-2,3-二氢-2-甲基-1H-二苯并[2,3:6,7]氧杂并[4,5-c]吡咯-1-酮(6)为起始原料,经还原反应合成杂质A,对A继续还原得到杂质B,利用氧气氧化杂质B可以得到杂质C;同样以6为起始物,经过二氧化锰氧化得到杂质D。结果与结论:目标化合物结构经1H-NMR,MS确证,HPLC检测纯度也都达到98%以上,合成的4种杂质可以作为阿塞那平药物质量控制的杂质对照品。该合成方法路线短,反应条件温和,原料易得,操作简单。 Objective : To synthesize four impurities of asenapine, in particular, the first reported synthesis of impurities C and D, for strengthening the quality control of asenapine. Methods: ll-Chloro-2,3-dihydro-2- methyl-I H-dibenz[2,3:6,7 ] oxepino[4,5-c ] pyrrol-1-one was used as starting material (6). Impurity A was ob- tained by reduction of 6, and impurity B was prepared by further reduction of A. Subsequently, oxidation of impu- rity B under O2 afforded impurity C. Similarly, oxidation of 6 by manganese dioxide afforded impurity D. Results and Conclusion: The structures of the target compounds were confirmed by 1H-NMR and MS, and their purities were over 98% tested by HPLC. These four synthesized impurities can be used as the reference substances of the impurities in the quality control of asenapine. This synthetic route is short, the condition is modest, and the materi- als are easy to get.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第9期1012-1014,1048,共4页 Chinese Journal of New Drugs
基金 国家“重大新药创制”科技重大专项(2011ZX09203-001-16)
关键词 阿塞那平 杂质 合成 氧化 还原 asenapine impurities synthesis oxidation reduction
  • 相关文献

参考文献11

  • 1王娟,李华芳.新型抗精神病药:阿塞那平[J].中国新药与临床杂志,2011,30(12):886-890. 被引量:3
  • 2王来海,张瑞岭,黄素培,王新友.新型非典型抗精神病药——阿塞那平[J].中国药房,2011,22(1):63-65. 被引量:5
  • 3惠子,董金华.阿塞那平(asenapine)[J].中国药物化学杂志,2010,20(2):156-156. 被引量:3
  • 4VADER J,ASPERSEN F,AGENAARS G.The syntheses of radiolabelled org 5222 and its main metabolite org5526[J].J Labelled Compd Radiopharm,1994,34(9): 845-867.
  • 5KEMPERMAN GJ,STUK TL.Process for the preparation of asenapine and intermendiate products used in said process: WO,2008003460[P].2008-01-10.
  • 6CZARNIK AW,RENON V.Deuterium-enriched asenapine: US,20090209608A1[P].2009-08-20.
  • 7HARRIS TW,SMITH HE,MOBLEY PL,et al.Affinity of 10-(4-methylpiperazino) dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain[J].J Med Chem,1982,25(7): 855-858.
  • 8LINDEN MVD,ROETERS T,HARTING R,et al.Debottlenecking the synthesis route of asenapine[J].Org Process Res Dev,2008,12(2): 196-201.
  • 9FUNKE CW,HINDRIKS H,SAM AP.Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate[J].Arzneimittelforschung,1990,40(5):536-539.
  • 10MENASRA H,KEDJADJA A,DEBACHE S,et al.Efficient synthesis of 3-pyrrolylquinolines via an 1,3-dipolar cycloaddition/oxidation Sequence[J].Synth Commun,2005,35(21): 2779-2788.

二级参考文献49

  • 1KEMPERMAN G J, STUK T L, LINDEN VAN DER J J M. Process for the preparation of asenapine and intermediate products used in said process: CN, 101484456 [ P]. 2009 - 07 - 15.
  • 2王维奇,池本哲哉. Method for producing dibenzoxepinopyrrole compound and its intermediate,and new intermediate:JP, 2007137877A[ P]. 2007 -06 -07.
  • 3德田修,王维奇,池本哲哉.阿塞那平合成中间体的制备方法:CN,1015633212A[P].2009-10-21.
  • 4SHAHID M, WALKER G B, ZOM S H, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature[ J]. J Psyehopharmacol,2009,23( 1 ) :65 - 73.
  • 5Weber J, McCormack PL. Asenapine[J]. CNS Drugs, 2009, 23(9) -781.
  • 6Marston HM, Young JW, Martin FD, et al. Asenapine effects in animal models of psychosis and cognitive function[J]. Psychopharmacology, 2009, 206 (4): 699.
  • 7Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale[J]. Psychopharmacol Bull, 2007, 40(2):41.
  • 8Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic[J], lnt J Clin Pract, 2009,63 (12) : 1 762.
  • 9Mclntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder[J]. Expert Rev Neurother, 2010, 10 ( 5 ) : 645.
  • 10Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability[J]. Drugs, 2008, 68(16) :2 269.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部